Earlier Access to Effective Treatments for Children with MS Reduces the Burden of Long-Term Disability
New research presented at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood significantly reduces long-term disability in multiple sclerosis patients.